ABBV vs NVS
AbbVie Inc. and Novartis AG, side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | ABBV | NVS |
|---|---|---|
| Revenue | $61.2B | $54.5B |
| Net income | $4.2B | $14.0B |
| Gross margin | 70.2% | 78.8% |
| Net margin | 6.9% | 25.6% |
| Return on equity | · | 31.0% |
| Diluted EPS | $2.36 | $7.15 |
| Dividend / share | $6.65 | · |
| Payout ratio | 275.8% | · |
| Free cash flow | $17.8B | $17.6B |
| Equity | $-3.3B | $46.1B |
| Net debt / equity | · | 0.37× |
| Current ratio | 0.67× | 1.12× |
| Revenue CAGR 5y | 6.0% | 2.3% |
| Profit CAGR 5y | −1.7% | 11.6% |
ABBV and NVS book revenue within 15% of each other, and NVS keeps more of each dollar of revenue as profit (25.6% against 6.9%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | ABBV | NVS |
|---|---|---|
| FY2025 | $61.2B | $54.5B |
| FY2024 | $56.3B | $50.3B |
| FY2023 | $54.3B | $45.4B |
| FY2022 | $58.1B | $42.2B |
| FY2021 | $56.2B | $42.8B |
| FY2020 | $45.8B | $48.7B |
| FY2019 | $33.3B | $47.5B |
| FY2018 | $32.8B | $44.8B |
| FY2017 | $28.2B | $42.4B |
| FY2016 | $25.6B | $48.5B |
Bottom line
| Fiscal year | ABBV | NVS |
|---|---|---|
| FY2025 | $4.2B | $14.0B |
| FY2024 | $4.3B | $11.9B |
| FY2023 | $4.9B | $14.8B |
| FY2022 | $11.8B | $7.0B |
| FY2021 | $11.5B | $24.0B |
| FY2020 | $4.6B | $8.1B |
| FY2019 | $7.9B | $11.7B |
| FY2018 | $5.7B | $12.6B |
| FY2017 | $5.3B | $7.7B |
| FY2016 | $6.0B | $6.7B |
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$6,628,000,000 | ABBV |
| FY2024 | +$6,017,000,000 | ABBV |
| FY2023 | +$8,878,000,000 | ABBV |
| FY2022 | +$15,848,000,000 | ABBV |
| FY2021 | +$13,416,000,000 | ABBV |
| FY2020 | −$2,855,000,000 | NVS |
| FY2019 | −$14,232,000,000 | NVS |
| FY2018 | −$12,080,000,000 | NVS |
| FY2017 | −$14,165,000,000 | NVS |
| FY2016 | −$22,880,000,000 | NVS |
The higher-revenue side has changed between ABBV and NVS over this period. The gap has narrowed since the earliest year compared.
10 of 15 comparable fiscal years — a year missing data on either side is not counted.
10 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −18.7 pp | NVS |
| FY2024 | −16.1 pp | NVS |
| FY2023 | −23.7 pp | NVS |
| FY2022 | +3.9 pp | ABBV |
| FY2021 | −35.6 pp | NVS |
| FY2020 | −6.5 pp | NVS |
| FY2019 | −1.0 pp | NVS |
| FY2018 | −10.8 pp | NVS |
| FY2017 | +0.6 pp | ABBV |
| FY2016 | +9.4 pp | ABBV |
The higher net margin has changed hands between ABBV and NVS over this period.
10 of 12 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NVS's net margin has been more volatile than ABBV's over the 10 comparable fiscal years — 11.6 percentage points of standard deviation against 6.3.
10 of 12 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between ABBV and NVS over these 10 fiscal years — ABBV led in 3 and NVS in 7.
10 of 12 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ABBV's return on equity has been more volatile than NVS's over the 6 comparable fiscal years — 33.2 percentage points of standard deviation against 11.2.
6 of 12 comparable fiscal years — a year missing data on either side is not counted.
Year by year
ABBV led in return on equity in every one of the 6 comparable fiscal years — a structural lead, not a recent swing.
6 of 12 comparable fiscal years — a year missing data on either side is not counted.